KRAS and lung cancer: Interestingly, COX-IS was not elevated in KRAS-mutant tumors (Supplementary Fig. S9K), demonstrating the advantage of utilizing a RAS transcriptional signature, rather than simply KRAS mutation status, to capture RAS signaling activity in human lung cancer.